About Us:
We are a biotech startup based in San Francisco, CA. We have developed a proprietary technology stack to generate the best TCE molecules. We can discover novel targets, generate binders with an >80% hit rate, and use proprietary AI models to predict potential on-target and off-target toxicity events with 100% accuracy to ensure clinical safety. We have an exciting pipeline coming up. Our team is interdisciplinary, consists of experienced immunologists, computational biologists and engineers who are dedicated to creating effective therapies to improve human health. Our advisory board consists of world-class biotech executives and experts in immuno-oncology who each has decades of experiences in bringing new immuno-oncology drugs to the clinic.
The Role:
Reporting to the Chief Executive Officer, the CSO/VP of Research is an accomplished scientific leader, who can professionally and effectively execute the research initiatives towards Shennon Bio’s vision and strategy. This role will lead the R&D function on the therapeutics side and play a critical part in developing biopharma partnerships. An ideal candidate will be an R&D leader with a passion for immunotherapy and knows how to bring TCE candidates into the clinic.
This person will maintain professional and productive relationships with internal colleagues and external collaborators with an entrepreneurial & go-to-market mindset. Shennon Bio’s vision of this candidate is an organized leader that has a self-starter attitude and a strong background in immune-oncology and TCE development.
Responsibilities
Qualifications and Experience:
Company Culture:
Collaboration, Ownership and Authenticity.

ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8.
www.shennonbio.com